Track DCOY and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap-
Enterprise Value-
Revenue (TTM)-
Net Income (TTM)-$12.52M
Free Cash Flow (TTM)-$4.83M
Financial Health
Cash$10.71M
Net Debt-$10.60M
Debt Ratio0.01
Debt to Equity0.02
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings-
EV to EBITDA-
Price to Book-
Price to Free Cash Flow-
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-223.18%
Return on Assets-149.65%
Return on Equity-231.20%
Return on Total Capital-223.18%
Return on Capital Employed-235.42%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-95.47%
Diluted EPS-0.04%
Total Debt-92.68%
Capital Expenditures194.61%
Free Cash Flow10.19%
CAGR (3Y)
Revenue0.00%
Diluted EPS0.16%
Total Debt0.00%
Capital Expenditures-27.27%
Free Cash Flow1000.00%
CAGR (1Y)
Revenue0.00%
Diluted EPS1000.00%
Total Debt-100.00%
Capital Expenditures1000.00%
Free Cash Flow-100.00%
$4.92-$0.39|-7.26%
52W High$13.51
52W Low$0.43
50D SMA$6.33
200D SMA$3.82
Volume14.31K
Decoy Therapeutics Inc.
2450 Holcombe Blvd, Houston, TX, United States, 77021
IPO
2026
Employees
11
Industry
Biotechnology
Sector
Healthcare
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Insider Transactions
Quarterly buy vs. sell activity
No insider transactions data available for this period
Analyst Ratings
No coverage data
No analyst ratings data available